All Oncology News

Assistant professor Lucia Borriello, of Fox Chase Cancer Center, was recently elected to the Board of Directors for the Metastasis Research Society.

Robert Lawrence Randall, MD, FACS, discusses the significance of risk-based therapy in patients with non-rhabdomyosarcoma soft tissue sarcoma.

Dana-Farber Cancer Institute is proud to announce the launch of the Direct Connect Partnership with Massachusetts Firefighters, addressing the heightened cancer risk faced by firefighters.

KT-333 was well tolerated in relapsed/refractory hematologic and solid tumor cancers, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.

Temple University Hospital has received re-accreditation under the American College of Surgeons, Commission on Cancer Accreditation Program.

Chih-Yi Liao, MD, discusses treatment considerations for patients with hepatocellular carcinoma and emphasizes the need for a multidisciplinary approach.

Anjana Pillai, MD, detailed how the treatment landscape for HCC is evolving, highlighting data from EMERALD-1.

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Roswell Park Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.

Pooja Murthy, MD, discusses second-line treatments in ER+/HER2– metastatic breast cancer for patients following progression on endocrine therapy plus a CDK4/6 inhibitor.

Chih-Yi Liao, MD, discusses the treatment landscape of advanced biliary tract cancer and outlines therapy selection factors.

Orelabrutinib plus FCG led to undetectable MRD in all patients with untreated chronic lymphocytic leukemia who completed 12 cycles of therapy

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status.

The FDA has granted fast track designation to the radiopharmaceutical 225Ac-FL-020 for patients with metastatic castration-resistant prostate cancer.

The FDA has granted fast track designation to Radspherin for the treatment of patients with peritoneal metastases from ovarian cancer.

Estelamari Rodriguez, MD, MPH, is breaking down barriers to care by creating Spanish-language content about lung cancer for patients and caregivers.

Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.

Anjana Pillai, MD, details a patient case study and key takeaways from a presentation she gave at an OncLive® State of the Science Summit™ on locoregional therapies for HCC.

The American Society for Radiation Oncology has released a guideline to characterize the place of radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma.

Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.

Tislelizumab plus chemotherapy improved OS in patients with unresectable esophageal squamous cell carcinoma and a CPS or TAP score of at least 1 vs 1%.

IBI343 was well tolerated and demonstrated signs of efficacy in patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma.

Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.

Cilta-cel improved overall survival vs standard regimens in relapsed/lenalidomide-refractory multiple myeloma after 1 prior line of therapy.

The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.

OncLive honors 15 oncology leaders with the 2024 Giants of Cancer Care awards for their innovations in improving patient outcomes.

Fox Chase Cancer Center celebrated a gift of $10.8 million from the Estate of Concetta “Chet” Greenberg, an ardent champion of cancer research during her life.

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.